Treatment of lymphomatoid papulosis with imiquimod 5% cream

Abstract

To the Editor: Lymphomatoid papulosis is a cutaneous primary CD30+ lymphoproliferative disorder related to mycosis fungoides with a chronic course and an increased risk of lymphoma.1 None of the current available therapies is curative and this subjects the patient to multiple repeated and protracted treatment cycles with attendant acute and long-term toxicity.2 Because lymphomatoid papulosis responds to systemic interferon alfa-2a with a 5-month remission3 and because mycosis fungoides (a related lymphoproliferative disease) responds to topical imiquimod 5% cream (an inducer of local interferon production),4 it seems reasonable that lymphomatoid papulosis might respond to topical imiquimod cream.